Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Haemorrhage/shock
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatHaemorrhage/shockControlledSprague-DawleyMalen = n = 11 per group in the four-group pre-treatment protocol;…Intravenous (tail vein for pre-treatment; femoral vein for post-resuscitation treatment)35 mg/kg in 1 mL saline (approximately 20 mM), selected aft…1 h before haemorrhagic shock induction or sham surgery in the main protocol, a…
Model: Haemorrhagic shock (bled to mean arterial pressure 30 mmHg maintained for 60 min) followed by resuscitation with shed blood, causing acute lung injury
Biliverdin given before haemorrhagic shock and resuscitation significantly reduced histopathological lung damage, neutrophil infiltration and oedema, lowered the 18-fold and 8-fold increases in tumour necrosis factor-alpha and inducible nitric oxide synthase expression, and returned mitochondrial 8…
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.